SCNI
Scinai Immunotherapeutics Ltd.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.12
P/S
0.64
EV/EBITDA
-0.43
DCF Value
$1.58
FCF Yield
-456.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-114.4%
Operating Margin
-556.4%
Net Margin
-634.1%
ROE
-93.0%
ROA
-67.3%
ROIC
-68.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $277.3K | $-2.1M | $-1.20 |
| Q2 2025 | $386.5K | $-2.1M | $-1.20 |
| Q1 2025 | $386.5K | $-1.5M | $-1.20 |
| Q4 2024 | $206.0K | $-2.2M | $-8.80 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.89
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.